Abstract
Culpepper et al. developed a novel bioengineered yeast-Saccharomyces boulardii-designed to specifically target exposed fibronectin in inflamed intestinal tissues and release anti-TNF nanobodies with the goal of reducing inflammation-driven tumorigenesis in a mouse model of colorectal adenocarcinoma.